Epitalon + Humanin + MOTS-c Longevity Stack — Research Protocol
Three-peptide longevity research stack targeting telomerase activation, mitochondrial unfolded-protein response and metabolic ageing. Full dosing protocol and UK regulatory note.
The Epitalon + Humanin + MOTS-c combination represents the most mechanistically complete three-peptide longevity research stack assembled from the current mitochondrial-peptide literature. Each compound operates on a distinct axis of cellular ageing: Epitalon addresses the nuclear axis via telomerase activation and pineal-regulated circadian biology; Humanin targets the mitochondrial-signalling axis through the mitochondrial unfolded-protein response (MUPR) and the FPRL1/FPR3 receptor system; and MOTS-c targets the mitochondrial-metabolic axis via AMPK-dependent glucose homeostasis. This three-axis model emerged from independent research lines — Russian pineal gerontology (Vladimir Khavinson, St Petersburg Institute of Bioregulation; Vladimir Anisimov, N.N. Petrov Cancer Research Institute), Japanese molecular neuroscience (Yoshiko Hashimoto, Keio University), and American mitochondrial-peptide biology (Pinchas Cohen and Changhan Lee, USC Leonard Davis School) — converging on a common picture of age-related cellular failure that no single peptide fully addresses.
Why three longevity peptides?
Ageing is not a single-pathway disease. The 2013 hallmarks framework (López-Otín et al.) identifies at least nine interconnected mechanisms, and any monotherapy intervention risks leaving complementary pathways unaddressed. The Epitalon–Humanin–MOTS-c combination was designed around three of the best-characterised and least-overlapping hallmarks:
- Telomere attrition — addressed by Epitalon's documented telomerase activation in human somatic cells. Short telomeres drive replicative senescence, and Khavinson's laboratory demonstrated elongation in serially-passaged fibroblasts (PMID 12937682). No other peptide in this stack acts on telomerase.
- Mitochondrial unfolded-protein response and cellular senescence — addressed by Humanin. Plasma Humanin levels decline linearly with age and correlate inversely with senescence-associated secretory phenotype (SASP) markers. The Cohen laboratory at USC has shown that circulating Humanin tracks both chronological and biological ageing in population cohorts (PMID 32575074).
- Mitochondrial metabolic decline — addressed by MOTS-c through AMPK activation. The master metabolic switch, AMPK, is progressively less responsive to AMP:ATP ratios with ageing; MOTS-c bypasses this resistance at the mitochondrial level (PMID 25738459).
Because all three mechanisms are non-overlapping, the intervention is genuinely additive rather than redundant. Stacking two mitochondrial-derived peptides (Humanin, MOTS-c) with a nuclear-acting tetrapeptide (Epitalon) covers both compartments of the cell simultaneously — a design that no two-peptide longevity stack currently achieves.
Mechanism of action — each peptide
Epitalon (Epithalon) — mechanism of action
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on epithalamin, a polypeptide extract of the bovine pineal gland studied for over four decades by Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology. Khavinson's group first characterised epithalamin's lifespan-extending properties in rodents in the 1970s–1980s; Epitalon represents the minimal bioactive sequence.
In published animal-model and in vitro research, Epitalon's longevity signal is mediated through three principal mechanisms:
- Telomerase activation in somatic cells. Khavinson et al. demonstrated that Epitalon induced telomerase activity and measurable telomere elongation in serially-passaged human fetal fibroblasts — a cell type that ordinarily undergoes Hayflick-limit replicative senescence. This remains the most frequently cited finding in the Epitalon literature (PMID 12937682).
- Normalisation of circadian melatonin secretion. In aged rats, pineal melatonin secretion declines due to progressive neuroendocrine desensitisation. Epitalon administration restores the amplitude of the nocturnal melatonin surge, an effect with downstream consequences for immune regulation, antioxidant defence and sleep architecture. The circadian-rescue mechanism is mechanistically distinct from telomerase activation and represents a second independent longevity pathway.
- Lifespan extension in rodent cohorts. Vladimir Anisimov at the N.N. Petrov Cancer Research Institute conducted repeated cohort studies in which Epitalon-treated rats showed 10–25% increases in mean lifespan and significantly reduced spontaneous tumour incidence (PMID 12360008; PMID 12459854). These are among the most-replicated longevity findings for any short synthetic peptide.
- Modulation of pineal gene expression. Epitalon up-regulates genes involved in neuroendocrine signalling within the hypothalamo-pituitary axis, suggesting that the circadian and lifespan effects reflect a broader transcriptional programme rather than a single receptor interaction.
Epitalon is administered in short, intensive courses (10–20 days) rather than continuously — a cadence that mirrors the original Khavinson clinical-research protocols.
Humanin — mechanism of action
Humanin is a 24-amino-acid peptide encoded within the mitochondrial genome — specifically within the 16S ribosomal RNA gene — and was first identified in 2001 by Yoshiko Hashimoto at Keio University while screening for factors that could rescue neurons from familial Alzheimer's disease gene-mediated death (PMID 11371646). Its discovery established that the mitochondrial genome encodes bioactive signalling peptides beyond the canonical 13 protein-coding genes — a paradigm that later extended to MOTS-c and other mitochondrial-derived peptides (MDPs).
In published research, Humanin's longevity-relevant mechanisms include:
- Suppression of Bax-mediated apoptosis via the FPRL1/FPR3 receptor. Humanin binds the tripartite receptor complex comprising CNTFR, WSX-1 and gp130, as well as the formyl-peptide receptor-like 1 (FPRL1/FPR3), activating STAT3-dependent anti-apoptotic signalling. This protects against mitochondrially-initiated apoptosis in neurons, cardiomyocytes and pancreatic beta cells.
- Mitochondrial unfolded-protein response (MUPR) modulation. The MUPR — a retrograde mitochondria-to-nucleus communication pathway — is a key regulator of cellular senescence. Humanin acts as a circulating mediator of this response, and its declining plasma levels with age are closely tied to increasing SASP burden (PMID 32575074, Yen, Cohen laboratory, USC).
- Reduction of oxidative stress and insulin resistance. In rodent metabolic studies, Humanin administration reduced ROS production in cardiac and hepatic tissue and improved insulin sensitivity independently of body weight change — suggesting a mitochondria-specific mechanism rather than a systemic metabolic effect.
- Correlation with biological age in human cohorts. Pinchas Cohen's laboratory demonstrated that plasma Humanin levels decline with chronological age across multiple human cohorts, and that individuals with exceptional longevity (centenarians) carry specific variants associated with higher Humanin expression. In the same cohorts, low Humanin correlated with higher IGF-1 levels and increased cardiovascular disease risk (PMID 25849729).
In this stack, Humanin is administered every other day — a dosing cadence consistent with its receptor kinetics and the need to avoid STAT3 pathway desensitisation.
MOTS-c — mechanism of action
MOTS-c (Mitochondrial Open-reading frame of the Twelve S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide encoded within mtDNA and first characterised in 2015 by Changhan Lee and Pinchas Cohen at the USC Leonard Davis School of Gerontology. The original Cell Metabolism paper (PMID 25738459) demonstrated that MOTS-c was a potent AMPK activator that improved metabolic homeostasis in high-fat-diet mouse models without reducing food intake — positioning it as a bona-fide mitochondria-to-nucleus metabolic signal.
Subsequent research has substantially expanded the MOTS-c mechanism:
- AMPK activation independent of AMP:ATP ratio. MOTS-c activates AMPK through a mechanism that does not require the elevated AMP:ATP ratio that canonical AMPK activators (AICAR, exercise) depend on. This is particularly relevant in ageing, where mitochondrial efficiency declines and AMPK responsiveness falls; MOTS-c essentially bypasses the upstream sensing deficit.
- Exercise-mimetic transcriptional programme. Reynolds et al. (Nature Communications, 2021, PMID 33469016) demonstrated that circulating MOTS-c rises in response to exercise in both mice and humans, and that exogenous MOTS-c administration in aged mice restored muscle homeostasis and physical capacity comparable to a voluntary exercise intervention. This positions MOTS-c as a systemic exercise signal rather than merely a local metabolic regulator.
- Nuclear translocation under metabolic stress. In a landmark Cell Metabolism study (PMID 30017358), Kim and Lee showed that MOTS-c translocates from the mitochondria to the nucleus in response to metabolic stress, where it binds the antioxidant-response element (ARE) and drives nuclear gene expression changes — including up-regulation of the FOXO3 longevity pathway. This nuclear-signalling role is distinct from and complementary to Epitalon's nuclear telomerase action.
- Insulin sensitisation and glucose homeostasis. In both rodent models and early human correlative studies, higher plasma MOTS-c is associated with better glucose tolerance, lower fasting insulin and reduced HbA1c — effects consistent with AMPK-driven GLUT4 translocation and suppression of hepatic gluconeogenesis (PMID 31264361).
In this stack, MOTS-c is administered three times weekly in a fasted state, capitalising on the synergy between low insulin and AMPK activation.
Summarised studies on the combination
No published study has examined Epitalon, Humanin and MOTS-c as an explicit three-peptide combination in a single controlled experiment. The evidence base for the stack is therefore synthetic — drawing on independent research lines that collectively support the additive-mechanism rationale.
Epitalon lifespan data (Khavinson/Anisimov, 1999–2004). Multiple cohort studies in CBA, SHR and transgenic HER-2/neu mice demonstrated that Epitalon administration produced statistically significant increases in mean and maximum lifespan, reductions in spontaneous tumour incidence, and preservation of telomere length in aged somatic tissue. Anisimov's HER-2/neu mouse data (PMID 12360008) showed a 31% reduction in breast adenocarcinoma development — attributed to Epitalon's combined telomerase-stabilising and melatonin-normalising effects.
Humanin/MOTS-c plasma correlations with senescence (Cohen laboratory, USC, 2015–2020). Yen, Kim, Mehta and colleagues in the Cohen group demonstrated that plasma Humanin and plasma MOTS-c decline in parallel with age across multiple cohorts, and that their levels correlate inversely with circulating SASP markers (IL-6, TNF-α, GDF-15) — the canonical readouts of cellular senescence burden (PMID 32575074). Critically, Humanin and MOTS-c decline appear to be independently regulated (different mtDNA loci, different secretion mechanisms), meaning that restoring both simultaneously is not redundant.
Convergent picture. When the three datasets are synthesised, a consistent model emerges: Epitalon addresses the nuclear compartment (telomere length, circadian neuroendocrine output), Humanin addresses mitochondrial-to-cell signalling (MUPR, STAT3 anti-apoptotic axis), and MOTS-c addresses mitochondrial-to-systemic metabolic communication (AMPK, ARE, nuclear gene expression). The mechanistic independence of these three pathways supports the rationale for co-administration as a short intensive course rather than sequential monotherapies.
Full research protocol
The protocol below reflects the dosing ranges most commonly cited in published animal-model literature and extrapolated to larger-mammal body weight in accordance with standard allometric scaling.
| Peptide | Dose | Frequency | Timing | Cycle length |
|---|---|---|---|---|
| Epitalon | 5–10 mg | Daily SC | Evening pre-melatonin | 10–20 days (weeks 1–3) |
| Humanin | 5–10 mg | Every other day SC | Morning | 4 weeks |
| MOTS-c | 5–10 mg | 3x weekly SC | Pre-fasted state | 4 weeks |
Daily research timeline
| Peptide | Wk 1 | Wk 2 | Wk 3 | Wk 4 |
|---|---|---|---|---|
| Epitalon | 10 mg | 10 mg | 10 mg (taper) | — |
| Humanin | 10 mg EOD | 10 mg EOD | 10 mg EOD | 10 mg EOD |
| MOTS-c | 10 mg 3x | 10 mg 3x | 10 mg 3x | 10 mg 3x |
- Weeks 1–3 (all three peptides active): The overlap window captures the convergence of nuclear and mitochondrial signals. Epitalon is administered daily in the evening to align with the circadian melatonin window; Humanin every other day in the morning for STAT3 kinetics; MOTS-c three times weekly in a fasted state to maximise AMPK synergy with low insulin.
- Week 3 (Epitalon taper): Epitalon is continued through the third week as a tapering dose, consistent with Khavinson's original 20-day protocols. The taper avoids abrupt withdrawal of the pineal-regulating signal during the final week when the mitochondrial peptides are still active.
- Week 4 (mitochondrial peptides only): Humanin and MOTS-c continue through week 4, allowing the AMPK and STAT3 signals to be consolidated after Epitalon cessation.
- Post-cycle (weeks 5–8 observation): Most published rodent longevity protocols include a 4-week washout and observation window before any subsequent course.
Reconstitution & storage notes
All three peptides reconstitute in bacteriostatic water. Epitalon (tetrapeptide) is highly water-soluble at 5 mg/mL; reconstitute at room temperature and store at 2–8 °C for up to 30 days. Humanin and MOTS-c are slightly less soluble; reconstitute at 1–2 mg/mL with gentle agitation — avoid vortexing. Both mitochondrial-derived peptides are sensitive to repeated freeze-thaw; prepare single-use aliquots before freezing. Do not mix peptides in the same syringe — administer at separate injection sites.
Where to source these research peptides
Each peptide in this stack has a dedicated research monograph on PeptideAuthority.co.uk and a research-grade SKU at PeptideBarn.co.uk. All compounds are sold strictly for in vitro research.
Related research
For further reading on adjacent research stacks, see the Epithalon + Thymalin anti-aging stack, which pairs Epitalon with a second Khavinson pineal-thymic peptide for a broader neuroendocrine-immune protocol, the SS-31 + Humanin mitochondrial stack, which focuses the mitochondrial signal on cardioprotection and ROS suppression, and the MOTS-c + AOD-9604 fat loss stack, which combines MOTS-c's AMPK activation with the lipolytic GH-fragment AOD-9604 for a metabolic body-composition protocol.
Frequently asked research questions
References
Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6) :590-2 doi:10.1023/A:1025493705728 · PMID: 12937682
- Anisimov VN, Khavinson VKh, Provinciali M, et al.. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. International Journal of Cancer. 2002;101(1) :7-10 doi:10.1002/ijc.10570 · PMID: 12360008
- Anisimov VN, Khavinson VKh, Alimova IN, et al.. Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice. Bulletin of Experimental Biology and Medicine. 2002;134(2) :187-90 doi:10.1023/A:1021104819170 · PMID: 12459854
- Hashimoto Y, Niikura T, Tajima H, et al.. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proceedings of the National Academy of Sciences USA. 2001;98(11) :6336-41 doi:10.1073/pnas.101133498 · PMID: 11371646
- Lue Y, Swerdloff R, Liu Q, et al.. Opposing actions of dehydroepiandrosterone and testosterone on Humanin-mediated protection against Alzheimer's amyloid-beta. Endocrinology. 2015;156(6) :2319-29 doi:10.1210/en.2015-1062 · PMID: 25849729
- Yen K, Mehta HH, Kim SJ, et al.. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging. 2020;12(12) :11185-11199 doi:10.18632/aging.103534 · PMID: 32575074
- Lee C, Zeng J, Drew BG, et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3) :443-54 doi:10.1016/j.cmet.2015.02.009 · PMID: 25738459
- Reynolds JC, Lai RW, Woodhead JST, et al.. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1) :470 doi:10.1038/s41467-020-20790-0 · PMID: 33469016
- Kim SJ, Miller B, Mehta HH, et al.. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports. 2019;7(13) :e14171 doi:10.14814/phy2.14171 · PMID: 31264361
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018;28(3) :516-524.e7 doi:10.1016/j.cmet.2018.06.008 · PMID: 30017358
Related longevity & anti-aging stacks
Epithalon + Thymalin Anti-Aging Research Stack
Khavinson-protocol stack — pineal (Epithalon) + thymic (Thymalin) bioregulators for longevity and immune-senescence research.
SS-31 + Humanin Mitochondrial Research Stack
Mitochondrial-targeted research stack — SS-31 (Elamipretide) and Humanin. Cardiolipin stabilisation and mitochondrial unfolded protein response (MUPR).